Stay updated with breaking news from கேய்ட் ஆர்ஃபர்ட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Calithera Biosciences, inc (CALA) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator Good day, and thank you for standing by. Welcome to the Calithera Biosciences First Quarter 2021 Earnings Call. [Operator Instructions] I would now like to hand the conference over to your first speaker today, Stephanie Wong. Please go ahead. Stephanie Wong Chief Financial Officer Thanks, Jeff. Good afternoon, everyone. Welcome to our first quarter 2021 Conference Call. Joining me today are Susan Molineaux, Founder, President and CEO; and Keith Orford Chief, Medical Officer. Earlier this afternoon, we issued a press release, which included an overview of our first quarter 2021 financial and operational results, which can be accessed through our website at calithera.com. Before we begin, I would like to remind you that today s discussion will include statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act ....
Calithera Biosciences Inc (CALA) Q4 2020 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Giving Immunotherapy a Helping Hand Source: Christoph Burgstedt/Science Photo Library/Getty Images Giving Immunotherapy a Helping Hand If adjusting one signal or hitting one target won’t force cancer to retreat, try adjusting multiple signals or deploying combination therapies Share Immunotherapy for cancer represents a promising alternative for many patients, but so far, it hasn’t delivered long-term benefits to a majority of patients as a standalone therapy. Fortunately, the immune system, with its complex webs of interacting networks and feedback pathways, offers myriad factors that drugs may target to summon tumor-killing resources. Druggable factors in the tumor microenvironment are now being sought by many developers. When these factors are engaged by therapeutic molecules, it is possible to clear away immune suppressors, to boost the cytotoxicity of immune cells, or to weaken a tumor’s defenses. ....